Breast cancer and ovarian cancer genetics

Journal of Long-Term Effects of Medical Implants

Volumn 15, Issue 5, 2005, Pages 533-545

  Edlich, Richard F ^a,b,c   Winters, Kathryne L ^c   Lin, Kant Y ^a,c  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b LEGACY EMANUEL HOSPITAL   (United States)

^c Department of Plastic Surgery ^*  (United States)

Author keywords

ATM gene; BRCA1 gene; BRCA2 gene; Breast and ovarian cancer prevention; Breast cancer; Chemoprevention; Diet and lifestyle; Genetic clinics; Genetic predisposition; HER 2 gene; Ovarian cancer; PTEN gene; Risk reducing mastectomies; TP53 gene

Indexed keywords

ALCOHOLS; BIOLOGICAL ORGANS; DISEASES; GENES; RISK ASSESSMENT;

BREAST CANCER; CANCER GENETICS; OVARIAN CANCER;

TUMORS;

ATM PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; TAMOXIFEN;

BLOOD CLOTTING DISORDER; BREAST CANCER; BREAST EXAMINATION; BREAST SURGERY; CANCER DIAGNOSIS; CANCER GENETICS; CANCER PREVENTION; CANCER RISK; CANCER SUSCEPTIBILITY; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIET; DRUG INDICATION; GENE MUTATION; GENETIC ANALYSIS; GENETIC COUNSELING; GENETIC PREDISPOSITION; GENETIC PROCEDURES; GENETIC RISK; GENETIC SCREENING; HETEROZYGOTE; HUMAN; LIFESTYLE; LUNG EMBOLISM; MAMMOGRAPHY; MASTECTOMY; ONCOGENE; OVARIECTOMY; OVARY CANCER; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SELF EXAMINATION; STROKE; THROMBOEMBOLISM;

EID: 27844571272     PISSN: 10506934     EISSN: None     Source Type: Journal    
DOI: 10.1615/JLongTermEffMedImplants.v15.i5.60     Document Type: Review

References (59)

1. American Cancer Society. Cancer facts and figures, 2003. http://www.cancer.org/downloads/stt/caff2003pwsecured.pdf.
2. National Cancer Institute, National Institutes of Health. Genetics of breast and ovarian cancer (PDQ). http://www.cancer.gov/cancerinfo/pdq/genetics/ breast-and-ovarian.
3. Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE, Lingenfelter B, Gumpper KL, Scholl T, Tavtigian SV, Pruss DR, Critchfield GC. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol. 2002;20(6):1480-90.
4. American Society of Clinical Oncology. Policy statement update: Genetic testing for cancer susceptibility. J Clin Oncol. 2003;21:2397-406.
5. American College of Medical Genetics Foundation. Genetic susceptibility to breast and ovarian cancer: assessment, counseling, and testing guidelines, 1999. http://www.health.state.ny.us/nysdoh/cancer/obcancer/contents.htm.
6. American College of Obstetricians and Gynecologists. Breast-ovarian cancer screening. Washington, DC: American College of Obstetricians and Gynecologists, 2000; ACOG Committee Opinion 239.
7. Slamon DJ, Godolphin W,Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244(4905):707-12
8. Pauletti G, Godolphin W, Press MF, Slamon DJ. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene. 1996;13:63-72.
9. Sauven P. Guidelines for the management of women at increased familial risk of breast cancer. Eur J Cancer. 2004;40(5):65 3-65.
10. Evans DGR, Burnell LD, Hopwood P, Howell A. Perception of risk in women with a family history of breast cancer. Br J Cancer. 1993;67:612-4.
11. Evans DGR, Blair V, Greenhalgh R, Hopwood P, Howell A. The impact of genetic counseling on risk perception in women with a family history of breast cancer. BrJ Cancer. 1994;70:934-8.
12. Hopwood P, Long A, Keeling F, Poole C, Evans DGR, Howell P. Psychological support needs for women at high genetic risk of breast cancer: some preliminary indicators. Psychooncology. 1998;7:403-12.
13. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers: Breast Cancer Linkage Consortium. Am J Hum Genet. 1995;56:265-71.
14. Blackwood MA, Weber BL. BRCA1 and BRCA2: from molecular genetics to clinical medicine. J Clin Oncol. 1998;16:1969-77.
15. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997;88:323-31.
16. Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990;250(4985):1233-8.
17. Sidransky D, Tokino T, Helzlsouer K, Zehnbauer B, Rausch G, Shelton B,Prestigiacomo L, Vogelstein B, Davidson N. Inherited p53 gene mutations in breast cancer. Cancer Res. 1992;52(10):2984-6.
18. Garber JE, Goldstein AM, Kantor AF, Dreyfus MG, Fraumeni JF Jr, Li FP. Follow-up study of twentyfour families with Li-Fraumeni syndrome. Cancer Res. 1991;51(22):6094-7.
19. Starink TM, van der Veen JPW, Arwert F, de Waal LP, de Lange GG, Gille JJP, Eriksson AW. The Cowden syndrome: a clinical and genetic study in 21 patients. Clin Genet. 1986;9:222-33.
20. Nelen MR, van Staveren WC, Peeters EA, Hassel MB, Gorlin RJ, Hamm H, Lindboe CF, Fryns JP, Sijmons RH, Woods DG, Mariman EC, Padberg GW, Kremer H. Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. Hum Mol Genet. 1997;6(8):1383-7.
21. Brownstein MH, Wolf M, Bilowski JB. Cowden's disease: a cutaneous marker of breast cancer. Cancer. 1978;41:2393Nelen MR, van Staveren CG, Peeters EAJ, Ben Hassel M, Gorlin RJ, Hamm H8.
22. Liaw D, Marsh DJ, Li J, Dahia PLM, Wang SI, Zheng Z, Bose S, Call KM, Tsou HC, Peacocke M, Eng C, Parsons R. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet. 1997;7:507-15.
23. Marsh DJ, Coulon V, Lunetta KL, Rocca-Serra P, Dahia PL, Zheng Z, Liaw D, Caron S, Duboue B, Lin AY, Richardson AL, Bonnetblanc JM, Bressieux JM, Cabarrot-Moreau A, Chompret A, Demange L, Eeles RA, Yahanda AM, Fearon ER, Fricker JP, Gorlin RJ, Hodgson SV, Huson S, Lacombe D, Eng C. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet. 1998;7(3):507-15.
24. Pilarski R, Eng C. Will the real Cowden syndrome please stand up (again)? Expanding mutational and clinical spectra of the PTEN hamartoma syndrome. J Med Genet. 2004;41:323-6.
25. Izatt L, Greenman J, Hodgson S, Ells D, Watts S, Scott G, Jacobs C, Liebmann R, Zvelebil MJ, Mathew C, Solomon E. Identification of germline missense mutations and rare allelic variants in the ATM gene in early-onset breast cancer. Genes Chromosomes Cancer. 1999;26(4):286-94.
26. Savitsky K, Sfez S, Tagle DA, Ziv Y, Sartiel A, Collins FS, Shiloh Y, Rotman G. The complete sequence of the coding region of the ATM gene reveals similarity to cell cycle regulators in different species. Hum Mol Genet. 1995;4(11):2025-32.
27. Swift M, Morrell D, Massey RB, Chase CL. Incidence of cancer in 161 families affected by ataxiatelangiectasia. N Engl J Med. 1991 Dec 26;325(26):1831-6.
28. FitzGerald MG, Bean JM, Hegde SR, Unsal H, MacDonald DJ, Harkin DP, Fikelstein DM, Isselbacher KJ, Haber DA. Heterozygous ATM mutations do not contribute to early onset of breast cancer. Nat Genet. 1997;15(3):307-10.
29. Slamon DJ, Clark GM,Wong SG, Levin WJ, Ulrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177-82.
30. Hudziak RM, Schlessinger J, Ulrich A. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Nad Acad Sci USA. 1987;84:7l59-63.
31. Di Fiore PP, Pierce JH, Krasu MH, Segatto O, King CR, Aaronson SA. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science. 1987:237:178-82.
32. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME, Shepard HM. Humanization of an anti-pl85HER2 antibody for human cancer therapy. Proc Nad Acad Sci U S A. 1992;89(10):4285-9.
33. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER-2 for metastatic breast cancer that overexpresses HER-2. N Engl J Med. 2001;344:783-92.
34. Schlemmer BO, Sorensen BS, Overgaard J, Olsen KE, Gjerdrum LM, Nexo E. Quantitative PCR-new diagnostic tool for quantifying specific mRNA and DNA molecules: HER2/neu DNA quantification with LightCycler real-time PCR in comparison with immunohitochemistry and fluorescence in situ hybridization. Scand J Clin Lab Invest. 2004;64:511-22.
35. Burke W, DaIy M, Garber J, Botkin J, Kahn MJ, Lynch P, McTiernan A, Offit K, Perlman J, Petersen G, Thomson E, Varricchio C. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA. 1997;277(12):997- 1003.
36. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N.Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90(18):1371-88.
37. Gail MH, Costantino JP, Bryant J, Croyle R, Freedman L, Helzlsouer K, Vogel V. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Nad Cancer Inst. 1999;91(21):1829-46.
38. Powles T, Eeles R, Ashley S, Easton D, Chang J, Dowsett M, Tidy A, Viggers J, Davey J. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet. 1998;352(9122):98-101.
39. Veronesi U, Maisonneuve P, Sacchini V, Rotmensz N, Boyle P. Tamoxifen for breast cancer among hysterectomised women. Lancet. 2002;359(9312):1122-4.
40. IBIS investigators. First results from the International Breast Cancer Intervention study (IBIS-1): a randomized prevention study. Lancet. 2002;360:817-24.
41. Eldar S, Meguid M, Beatty JD. Cancer of the breast after prophylactic subcutaneous mastectomy. Am J Surg. 1984;148:692-3.
42. Willemsen H, Kaas R, Peterse JH, Rutgers EJ. Breast carcinoma in residual breast tissue after bilateral subcutaneous mastectomy. Eur J Surg Oncol. 1998;24:331-8.
43. Zeigler LD, Kroll SS. Primary breast cancer after prophylactic mastectomy. Am J Clin Oncol. 1991;14:451-4.
44. Lagios MD, Gates EA, Westdahl PR, Richards V, Alpert BS. A guide to the frequency of nipple involvement in breast cancer. Am J Surg. 1979;138:135-40.
45. Pennisi VR, Capozzi A, Perez F. Subcutaneous mastectomy data: a preliminary report. Plastic Reconstr Surg. 1997;59:53-6.
46. Pennisi VR, Capozzi A. Subcutaneous mastectomy data: a final statistical analysis of 1500 patients. Aesthetic Plast Surg. 1989;13:15-21.
47. Meijers-Heijboer H, van Geel B, van Putten WL, Henzen-Logmans SC, Seynaeve C, Menke-Pluymers MB, Bartels CC, Verhoog LC, van den Ouweland AM, Niermeijer MF, Brekelmans CT, Klijn JG. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2001;345(3):159-64.
48. Hartmann LC, Sellers TA, Schaid DJ, Frank TS, Soderberg CL, Sitta DL, Frost MH, Grant CS, Donohue JH, Woods JE, McDonnell SK, Vockley CW, Deffenbaugh A, Couch FJ, Jenkins RB. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst. 2001;93(21):1633-7.
49. Hartmann LC, Schaid DJ, Woods JE, Crotty TP, Myers JL, Arnold PG, Petty PM, Sellers TA, Johnson JL, McDonnell SK, Frost MH, Jenkins RB. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med. 1999;340(2):77-84.
50. Rebbeck TR, Levin AM, Eisen A, Snyder C, Watson P, Cannon-Albright L, Isaacs C, Olopade O, Garber JE, Godwin AK, Daly MB, Narod SA, Neuhausen SL, Lynch HT, Weber BL. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst. 1999;91(17):1475-9.
51. Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, Ellis NA, Boyd J, Borgen PI, Barakat RR, Norton L, Castiel M, Nafa K, Offit K. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2002;346(21):1609-15.
52. Kerlikowske K, Carney PA, Geller B, Mandelson MT, Taplin SH, Malvin K, Ernster V, Urban N, Cutter G, Rosenberg R, Ballard-Barbash R. Performance of screening mammography among women with and without a first-degree relative with breast cancer. Ann Intern Med. 2000;133(11):855-63.
53. Macmillan RD. Screening women with a family history of breast cancer-results from the British Familial Breast Cancer Group. Eur J Surg Oncol. 2000;26:149-52.
54. Kolb M, Lichy J, Newhouse JH. Comparison of the performance of screening mammography, physical examination, and breast us and evaluation of factors that influence them: an analysis of 27,825 patient evaluations. Radiology. 2002;225:165-75.
55. Kuhl CK, Schmutzler RK, Leutner CC, Kempe A, Wardelmann E, Hocke A, Maringa M, Pfeifer U, Krebs D, Schild HH. Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: preliminary results. Radiology. 2000;215(1):267-79.
56. Stoutjesdijk MJ, Boetes C, Jager GJ, Beex L, Bult P, Hendriks JH, Laheij RJ, Massuger L, van Die LE, Wobbes T, Barentsz JO. Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer. J Natl Cancer Inst. 2001;93(14):1095-102.
57. Warner E, Plewes DB, Shumak RS, Catzavelos GC, Di Prospero LS, Yaffe MJ, Goel V, Ramsay E, Chart PL, Cole DE, Taylor GA, Cutrara M, Samuels TH, Murphy JP, Murphy JM, Narod SA. Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer. J Clin Oncol. 2001;19(15):3524-31.
58. Sirovich BE, Sox HC Jr. Breast cancer screening. Surg Clin North Am. 1999;79(5):961-90.
59. Gui GPH, Hogben RKF, Walsh G, A'Hern R, Eeles R. The incidence of breast cancer form screening women according to predicted family history risk. Does annual clinical examination add to mammography? Eur J Cancer. 2001;37(13):1668-73.